The serum levels of PIVKA II, ucMGP, CEA, and CA 19-9 were assessed in order to evaluate the possibility of their use in the screening, diagnosis, and follow-up of colorectal cancer. This evidence concerns the gene CEACAM5 and colorectal cancer.